主动监测中系列MRI与重复活检对前列腺癌升级的评估
该回顾性研究纳入111例低危前列腺癌患者,在主动监测1年时进行重复MRI及靶向和系统活检。MRI阳性者升级率显著高于MRI阴性者(48% vs 10%),且MRI阳性者中系统活检有额外价值,而MRI阴性者系统活检的额外价值有限。
要点
- MRI阳性者1年升级率48%,显著高于MRI阴性者的10%。
- MRI阳性者中,仅靶向活检漏检23%的升级,仅系统活检漏检33%。
- MRI阴性者重复系统活检的额外价值有限,需个体化权衡。
核心结论
- 在主动监测1年时,MRI阴性者升级率显著低于MRI阳性者。
- 系列MRI阴性者重复系统活检的额外价值有限,应个体化权衡利弊。
- 系列MRI阳性者重复系统活检的额外价值显著,推荐联合靶向活检进行。
研究设计与样本
- 回顾性纳入111例低危(ISUP分级1)前列腺癌患者。
- 在主动监测1年时按方案进行重复MRI,并酌情行靶向活检和重复系统活检。
- 靶向活检针对PI-RADS评分≥3的病灶(MRI阳性者)。
主要发现
- 总体升级(ISUP≥2)率为32%(35/111)。
- MRI阳性者升级率48%(30/63),MRI阴性者10%(5/48),P<0.001。
- MRI阳性者中,仅靶向活检发现升级者占23%(7/30),仅系统活检发现者占33%(10/30)。
- MRI阳性者中,放射学进展(PRECISE 4-5)者升级率41%(7/17),无进展者50%(23/46),P=0.534。
- 总体升级(ISUP≥2伴筛状/导管内癌)率15%(17/111),MRI阳性者22%(14/63),MRI阴性者6%(3/48),P=0.021。
关键数值与推荐
- 靶向活检指征为PI-RADS评分≥3的病灶。
- 升级定义包括ISUP≥2、ISUP≥2伴筛状生长/导管内癌、ISUP≥3。
- 放射学进展定义为PRECISE评分4-5。
临床怎么用
- 对主动监测1年时的MRI阳性者,推荐联合靶向活检和系统活检,无论有无放射学进展。
- 对系列MRI阴性者,重复系统活检的价值有限,应个体化决策并权衡 harms。
局限性
- 回顾性研究设计。
- 样本量有限(111例)。
- 单中心队列,结论需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether serial prostate magnetic resonance imaging (MRI) may guide the utility of repeat targeted (TBx) and systematic biopsy (SBx) when monitoring men with low-risk prostate cancer (PCa) at 1-year of active surveillance (AS). PATIENTS AND METHODS: We retrospectively included 111 consecutive men with low-risk (International Society of Urological Pathology [ISUP] Grade 1) PCa, who received protocolled repeat MRI with or without TBx and repeat SBx at 1-year of AS. TBx was performed in Prostate Imaging-Reporting and Data System (PI-RADS) score ≥3 lesions (MRI-positive men). Upgrading defined as ISUP Grade ≥2 PCa (I), Grade ≥2 with cribriform growth/intraductal carcinoma PCa (II), and Grade ≥3 PCa (III) was investigated. Upgrading detected by TBx only (not by SBx) and SBx only (not by TBx) was investigated in MRI-positive and -negative men, and related to radiological progression on MRI (Prostate Cancer Radiological Estimation of Change in Sequential Evaluation [PRECISE] score). RESULTS: Overall upgrading (I) was 32% (35/111). Upgrading in MRI-positive and -negative men was 48% (30/63) and 10% (5/48) (P < 0.001), respectively. In MRI-positive men, there was upgrading in 23% (seven of 30) by TBx only and in 33% (10/30) by SBx only. Radiological progression (PRECISE score 4-5) in MRI-positive men was seen in 27% (17/63). Upgrading (I) occurred in 41% (seven of 17) of these MRI-positive men, while this was 50% (23/46) in MRI-positive men without radiological progression (PRECISE score 1-3) (P = 0.534). Overall upgrading (II) was 15% (17/111). Upgrading in MRI-positive and -negative men was 22% (14/63) and 6% (three of 48) (P = 0.021), respectively. In MRI-positive men, there was upgrading in three of 14 by TBx only and in seven of 14 by SBx only. Overall upgrading (III) occurred in 5% (five of 111). Upgrading in MRI-positive and -negative men was 6% (four of 63) and 2% (one of 48) (P = 0.283), respectively. In MRI-positive men, there was upgrading in one of four by TBx only and in two of four by SBx only. CONCLUSION: Upgrading is significantly lower in MRI-negative compared to MRI-positive men with low-risk PCa at 1-year of AS. In serial MRI-negative men, the added value of repeat SBx at 1-year surveillance is limited and should be balanced individually against the harms. In serial MRI-positive men, the added value of repeat SBx is substantial. Based on this cohort, SBx is recommended to be performed in combination with TBx in all MRI-positive men at 1-year of AS, also when there is no radiological progression.
引用
- Osses DF, Drost FH, Verbeek JFM, et al. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary? BJU Int. 2020. PMID: 32232921. doi:10.1111/bju.15065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。